Pharmaceutical Technology Europe
When validating automated systems from third-party providers, using the V model and failure modes effects and criticality analysis (FMECA) early in the process can help.
Peter Woods
Advertisement
Peter Woods is Programme manager at GB Innomech Ltd (UK).
Articles by Peter Woods
Advertisement
Latest Updated Articles
The benefits of risk-based analyses during system validationSeptember 1st 2009
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Leveraging an Innovative Mid-Scale Manufacturing Solution to Meet Diverse Needs
2
Renewing Prosaic Generics for Cancer Treatment
3
Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance
4
Faster Doesn’t Mean Easier: Development Impacts of a New Biosimilar Regulatory Landscape
5